PHAGOTHERAPY AS AN ALTERNATIVE METHOD OF ANTIMICROBIAL TREATMENT IN INDIVIDUALS WITH DRUG ALLERGY: A CLINICAL OBSERVATION
DOI:
https://doi.org/10.11603/1681-2727.2025.3.15495Keywords:
urinary tract infection, phage therapy, dysbiosis, biocorrection, Klebsiella oxytocaAbstract
SUMMARY. Bacteriophage therapy is considered an alternative method of antimicrobial treatment of urinary tract infections in patients with drug allergy, particularly in cases of anaphylactic-type hypersensitivity to beta-lactam antibiotics.
This clinical case demonstrates the effectiveness of phage therapy in a patient with drug allergy who developed cystitis caused by Klebsiella oxytoca.
Repeated microbiological examinations confirmed a decrease in bacterial count in the urine, followed by their complete elimination after intravesical administration of the bacteriophage through a catheter, as well as the eradication of Acinetobacter.
In the presence of intestinal dysbiosis, biocorrective therapy was carried out, and its effectiveness was confirmed by microbiological methods.
The prescription of phage therapy should be based on the results of specific microbiological diagnostics and determination of pathogen sensitivity to bacteriophages.
The effectiveness of phage therapy can be enhanced through microbiocenosis biocorrection, provided dysbiotic changes are identified.
References
Литвиненко, Т. А., & Нікітін, В. О. (2021). Фаготерапія як метод альтернативного лікування антибіотикорезистентних інфекцій у пацієнтів з медикаментозною алергією. Інфекційні хвороби, 2, 42–47.
Chegini, Z., Khoshbayan, A., Vesal, S., Moradabadi, A., Hashemi, A., & Shariati, A. (2021). Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review. Annals of clinical microbiology and antimicrobials, 20(1), 30. https://doi.org/10.1186/s12941-021-00433-y DOI: https://doi.org/10.1186/s12941-021-00433-y
Paczosa, M. K., & Mecsas, J. (2016). Klebsiella pneumoniae: going on the offense with a strong defense. Microbiology and molecular biology reviews, 80(3), 629-661.https://doi.org/10.1128/MMBR.00078-15 DOI: https://doi.org/10.1128/MMBR.00078-15
Yahya, R., Albaqami, A., Alzahrani, A., Althubaiti, S. M., Alhariri, M., Alrashidi, E. T., ... & Alharbi, N. (2025). Comprehensive genomic analysis of Klebsiella pneumoniae and its temperate N-15-like phage: From isolation to functional annotation. Microorganisms, 13(4), 908. https://doi.org/10.3390/microorganisms13040908 DOI: https://doi.org/10.3390/microorganisms13040908
Hatfull, G. F., Dedrick, R. M., & Schooley, R. T. (2022). Phage therapy for antibiotic-resistant bacterial infections. Annual review of medicine, 73(1), 197-211. https://doi.org/10.1146/annurev-med-042220-013154 DOI: https://doi.org/10.1146/annurev-med-080219-122208
Górski, A., Jończyk-Matysiak, E., Łusiak-Szelachowska, M., Międzybrodzki, R., Weber-Dąbrowska, B., & Borysowski, J. (2018). Phage therapy in allergic disorders? Experimental biology and medicine (Maywood, N.J.), 243(6), 534–537. https://doi.org/10.1177/1535370218755658 DOI: https://doi.org/10.1177/1535370218755658
Międzybrodzki, R., Borysowski, J., Kłak, M., Jończyk-Matysiak, E., Obmińska-Mrukowicz, B., Suszko-Pawłowska, A., ... & Górski, A. (2017). In vivo studies on the influence of bacteriophage preparations on the autoimmune inflammatory process. BioMed research international, 2017(1), 3612015. https://doi.org/10.1155/2017/3612015 DOI: https://doi.org/10.1155/2017/3612015
Xing, J., Han, R., Zhao, J., Zhang, Y., Zhang, M., Zhang, Y., Zhang, H., Nang, S. C., Zhai, Y., Yuan, L., Wang, S., & Wu, H. (2025). Revisiting therapeutic options against resistant klebsiella pneumoniae infection: Phage therapy is key. Microbiological research, 293, 128083. https://doi.org/10.1016/j.micres.2025.128083 DOI: https://doi.org/10.1016/j.micres.2025.128083
Wright, G., Michniewski, S., & Jameson, E. (2025). DepoRanker: A Web Tool to predict Klebsiella Depolymerases using Machine Learning. arXiv preprint arXiv:2501.16405. https://doi.org/10.48550/arXiv
Gelman, D., Eisenkraft, A., Chanishvili, N., Nachman, D., Glazer, S. C., & Hazan, R. (2018). The history and promising future of phage therapy in the military service. Journal of Trauma and Acute Care Surgery, 85(1S), S18-S26. https://doi.org/10.1097/TA.0000000000001850 DOI: https://doi.org/10.1097/TA.0000000000001809
Fayez, M. S., Abdel-Rahman, M. A., Hamed, R. R., & El-Badawy, M. (2021). Bacteriophages of Klebsiella pneumoniae: Diversity, therapeutic applications, and host interactions. Antibiotics, 10(9), 1048. https://doi.org/10.3390/antibiotics10091048 DOI: https://doi.org/10.3390/antibiotics10091048
Mkilima, T. (2025). Engineering artificial microbial consortia for personalized gut microbiome modulation and disease treatment. Annals of the New York Academy of Sciences. https://doi.org/10.3389/fmicb.2023.1172635 DOI: https://doi.org/10.1111/nyas.15352
Cui, L., Watanabe, S., Miyanaga, K., Kiga, K., Sasahara, T., Aiba, Y., ... & Wannigama, D. L. (2024). A comprehensive review on phage therapy and phage-based drug development. Antibiotics, 13(9), 870. https://doi.org/10.3390/antibiotics1309087 DOI: https://doi.org/10.3390/antibiotics13090870
Chen, X., Liu, M., Zhang, P., Leung, S. S. Y., & Xia, J. (2021). Membrane-permeable antibacterial enzyme against multidrug-resistant Acinetobacter baumannii. ACS Infectious Diseases, 7(8), 2192-2204. https://doi.org/10.3389/fmicb.2021.698257 DOI: https://doi.org/10.1021/acsinfecdis.1c00222
Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., ... & Lavigne, R. (2014). Engineered endolysin-based “Artilysins” to combat multidrug-resistant gram-negative pathogens. MBio, 5(4), 10-1128. https://doi.org/10.1128/mBio.01379-14 DOI: https://doi.org/10.1128/mBio.01379-14
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 О. П. Корнійчук, М. О. Секунда, Г. С. Лаврик, Т. М. Руминська
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
